Shernan Holtan: A signal of protection from myeloid neoplasms by GLP-1RA
Shernan Holtan, Chief of Blood and Marrow Transplantation and Professor of Medicine at Roswell Park Comprehensive Cancer Center, shared a post on LinkedIn about a paper by Omer Ashruf et al. published in JAMA Network Open:
“The GLP1RA hits keep rolling in. Here is a signal of protection from myeloid neoplasms. Fascinating how many diseases these drugs appear to influence! If true, the reduced burden of many diseases with the use of these drugs is at the societal level.”
“Hematologic Cancers Among Patients With Type 2 Diabetes Prescribed GLP-1 Receptor Agonists”
Authors: Omer Ashruf, Jasmin Hundal, Ali Mushtaq, David Kaelber, Faiz Anwer, Abhay Singh.
This retrospective cohort study analyzed the association between glucagon-like peptide–1 receptor agonists (GLP-1RAs) and the risk of hematologic cancers in patients with type 2 diabetes (T2D), using data from the TriNetX electronic health record repository. Patients prescribed GLP-1RAs (e.g., semaglutide, liraglutide) were compared with those on metformin or insulin.
After propensity matching, GLP-1RA use was associated with a significantly lower risk of myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN) compared with metformin, and a significantly reduced risk of multiple hematologic cancers – including leukemia, lymphoma, MDS, MPN, and multiple myeloma – compared with insulin.
These findings suggest a potential protective role of GLP-1RAs, possibly due to weight loss and immunomodulation. However, limitations such as reliance on encounter codes and lack of age stratification warrant further research to confirm these associations.
More posts featuring Shernan Holtan.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023